Justification of the program therapy of acute hepatitis C
https://doi.org/10.22625/2072-6732-2011-3-3-52-55
Abstract
Treatment of acute hepatitis C remains one of the main problems of modern hepatology. There are many variants of treatment, but there is no common opinion about scheme and time of onset of the therapy. From the other hand, early treatment can prevent chronisation in more than 70% of cases. Specific therapy was used 135 patients with acute hepatitis C aged from 16 to 52 years (26,5+0,7 years). Our analysis has shown, that its better to start specific therapy on the second month of the disease with -interferon monotherapy by induction scheme.
About the Authors
E. A. Mikhailova
Nizhegorodskaya State Medical Academy, Nizhniy Novgorod
Russian Federation
Russian Federation
O. L. Sobolevskaya
Nizhegorodskaya State Medical Academy, Nizhniy Novgorod
Russian Federation
Russian Federation
References
1. Jackel, E. The course and therapy of acute hepatitis C viral infection. Is a prevention of its becoming chronic possible? / . Jackel, M.P. Manns // Z. Gastroenterol. – 2000. – № 38. – P. 387–395.
2. Gerlach, T.J. Acute hepatitis C: Natural course and response to antiviral treatment / T.J. Gerlach [et al.] /Hepatology. – 2001. – № 34. – P. 341.
3. Wedemeyer, H. Whom? When? How? Another piece of evidence for early treatment of acute hepatitis C / H. Wedemeyer [et al.] // Hepatology. – 2004. – № 39. – P. 1201–1203.
4. Бакулин, И.Г. Актуальные вопросы противовирусной терапии хронических гепатитов В и С / И.Г. Бакулин // Эксперим. и клинич. гастроэнтерология. – 2010. – № 5. – С. 3–9.
5. Magnia, A. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial / A. Magnia [et al.] // Hepatology. – 2008. – № 47. – P. 43–50.
6. Wiegand, J. Treatment of acute hepatitis C: the success of monotherapy with (pegylated) interferon alpha / J. Wiegand [et al.] // J. Antimicrob Chemother. – 2008. – № 62. – P. 860–865.
7. Конусова, В.Г. Изменение показателей оксидантного и цитокинововго статуса больных хроническим гепатитом С и В при лечении препаратом рекомбинантного интерлейкина 1β человека / В.Г. Конусова [и др.] // Цитокины и воспаление. – 2003. – Т. 2, № 1. – С. 20–28.
Review
For citations:
Mikhailova E.A., Sobolevskaya O.L. Justification of the program therapy of acute hepatitis C. Journal Infectology. 2011;3(3):52-55. (In Russ.) https://doi.org/10.22625/2072-6732-2011-3-3-52-55
Views:
677
.png)
.png)
Email this article 